Patents by Inventor Jérôme BINET

Jérôme BINET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
    Patent number: 12161650
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: December 10, 2024
    Assignee: ARMGO Pharma, Inc.
    Inventors: Eugene E. Marcantonio, Mette Uhre Anby, Jérôme Binet
  • Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
    Patent number: 12059426
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Grant
    Filed: July 13, 2023
    Date of Patent: August 13, 2024
    Assignee: ARMGO Pharma, Inc.
    Inventors: Eugene E. Marcantonio, Mette Uhre Anby, Jérôme Binet
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF
    Publication number: 20230372358
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Application
    Filed: July 25, 2023
    Publication date: November 23, 2023
    Inventors: Eugene E. MARCANTONIO, Mette Uhre ANBY, Jérôme BINET
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF
    Publication number: 20230364107
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Application
    Filed: July 13, 2023
    Publication date: November 16, 2023
    Inventors: Eugene E. MARCANTONIO, Mette Uhre ANBY, Jérôme BINET
  • Pharmaceutical compositions comprising a ryanodine receptor modulator and uses thereof
    Patent number: 11717526
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: August 8, 2023
    Assignee: ARMGO Pharma, Inc.
    Inventors: Eugene E. Marcantonio, Mette Uhre Anby, Jérôme Binet
  • PHARMACEUTICAL COMPOSITIONS COMPRISING A RYANODINE RECEPTOR MODULATOR AND USES THEREOF
    Publication number: 20220387442
    Abstract: The present disclosure provides a modified-release pharmaceutical composition comprising 4-[(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)yl)methyl]benzoic acid hemifumarate, and a pharmaceutically-acceptable excipient. The present disclosure methods of treating conditions associated with RyRs, including, for example, cardiac disorder or disease, a musculoskeletal disorder or disease, cancer associated muscle weakness, malignant hyperthermia, and diabetes.
    Type: Application
    Filed: May 19, 2022
    Publication date: December 8, 2022
    Inventors: Eugene E. MARCANTONIO, Mette Uhre ANBY, Jérôme BINET